Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.58 |
| ▸ | LMNA | P02545 | 2/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | HTT | P42858 | 1/20 | 0.58 |
| ▸ | NPC1 | O15118 | 6/20 | 0.55 |
| ▸ | RAB9A | P51151 | 5/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.46 |
| ▸ | ELOVL1 | Q9BW60 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | IDO1 | P14902 | 1/20 | 0.44 |
| ▸ | RAF1 | P04049 | 1/20 | 0.43 |
| ▸ | GRM5 | P41594 | 1/20 | 0.43 |
| ▸ | CTSK | P43235 | 1/20 | 0.43 |
| ▸ | GCK | P35557 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16703930 | 0.85 | SMN1; SMN2 (0.54) | SMN1; SMN2ALDH1A1LMNAKDM4EHTT | |
| SCHEMBL16698703 | 0.81 | SMN1; SMN2 (0.54) | SMN1; SMN2ALDH1A1LMNAKDM4EHTT | |
| SCHEMBL16699478 | 0.81 | SMN1; SMN2 (0.54) | SMN1; SMN2ALDH1A1LMNAKDM4EHTT | |
| SCHEMBL11565633 | 0.81 | SMN1; SMN2 (0.50) | SMN1; SMN2ALDH1A1LMNAKDM4EHTT | |
| SCHEMBL18421576 | 0.79 | NPC1 (0.65) | SMN1; SMN2ALDH1A1LMNAKDM4EHTT | |
| SCHEMBL2629347 | 0.79 | SMN1; SMN2 (0.64) | SMN1; SMN2ALDH1A1LMNAKDM4EHTT | |
| SCHEMBL2625578 | 0.79 | NPC1 (0.57) | SMN1; SMN2ALDH1A1LMNAKDM4EHTT | |
| SCHEMBL16703928 | 0.79 | SMN1; SMN2 (0.51) | SMN1; SMN2ALDH1A1LMNAKDM4EHTT | |
| SCHEMBL19116503 | 0.78 | SMN1; SMN2 (0.67) | SMN1; SMN2ALDH1A1LMNAKDM4EHTT | |
| SCHEMBL12444121 | 0.78 | SMN1; SMN2 (0.62) | SMN1; SMN2ALDH1A1LMNAKDM4EHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240207267-A1 | (R)-Glutarimide CRBN Ligands and Methods of Use | BEIGENE SWITZERLAND GMBH (CH) | 2024-06-27 | — | — | US | disclosed |
| US-20240207267-A1 | (R)-Glutarimide CRBN Ligands and Methods of Use | BEIGENE SWITZERLAND GMBH (CH) | 2024-06-27 | — | — | US | disclosed |
| WO-2023109944-A1 | TLR MODULATOR AND USE THEREOF | 映恩生物制药（苏州）有限公司 | 2023-06-22 | — | — | WO | disclosed |
| US-20230026856-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | SPARCBIO LLC | 2023-01-26 | — | — | US | disclosed |
| US-20170362234-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2017-12-21 | — | — | US | disclosed |
| US-20170362234-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2017-12-21 | — | — | US | disclosed |
| US-20170355705-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2017-12-14 | — | — | US | disclosed |
| US-8153793-B2 | Sulfonamide derivative having PGD2 receptor antagonistic activity | SHIONOGI & CO., LTD. (JP) | 2012-04-10 | — | — | US | disclosed |
| EP-1928236-B1 | DIARYLAMINE-CONTAINING COMPOUNDS AND COMPOSITIONS, AND THEIR USE AS MODULATORS OF C-KIT RECEPTORS | IRM LLC (BM) | 2011-11-23 | — | — | EP | disclosed |
| EP-2190836-B1 | 2-HETEROARYLAMINO-PYRIMIDINE DERIVATIVES AS KINASE INHIBITORS | IRM LLC (BM) | 2011-08-17 | — | — | EP | disclosed |
| US-7902204-B2 | 2-(4-Benzoyl-piperazin-1-yl)-3-(4-chloro-5H-pyrrolo[3,2-d]pyrimidin-7-yl)-3-oxo-propionitrile; HIV and AIDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-03-08 | — | — | US | disclosed |
| EP-1751161-B1 | DIAZAINDOLE-DICARBONYL-PIPERAZINYL ANTIVIRAL AGENTS | BRISTOL MYERS SQUIBB CO (US) | 2010-07-14 | — | — | EP | disclosed |
| US-20080125439-A1 | DIAZAINDOLE-DICARBONYL-PIPERAZINYL ANTIVIRAL AGENTS | BRISTOL-MYERS SQUIBB COMPANY | 2008-05-29 | — | — | US | disclosed |
| US-4166123-A | ANTIALLERGENS | LILLY INDUSTRIES LIMITED (GB) | 1979-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080125439-A1 | DIAZAINDOLE-DICARBONYL-PIPERAZINYL ANTIVIRAL AGENTS | ZC3HAV1, ZC3HAV1L, EIF2AK2 | SMN1; SMN2 4486/4885ALDH1A1 2394/4885LMNA 2812/4885 |
| US-20170355705-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | SMN1; SMN2 2016/4885ALDH1A1 993/4885LMNA 3510/4885 |
| US-20240207267-A1 | (R)-Glutarimide CRBN Ligands and Methods of Use | CRBN, CDR2, CRKL | SMN1; SMN2 2282/4885ALDH1A1 2445/4885LMNA 2226/4885 |
| US-20170362234-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | SMN1; SMN2 1917/4885ALDH1A1 1067/4885LMNA 3512/4885 |
| US-20230026856-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | KRAS, NRAS, HRAS | SMN1; SMN2 2473/4885ALDH1A1 2350/4885LMNA 1904/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.